Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1

Michael Y. Choi, George F. Widhopf, Christina C.N. Wu, Bing Cui, Fitzgerald Lao, Anil Sadarangani, Joy Cavagnaro, Charles Prussak, Dennis A. Carson, Catriona Jamieson, Thomas J. Kipps

Research output: Contribution to journalReview articlepeer-review

84 Scopus citations


Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncoembryonic antigen. Because of its expression on the cell surface of leukemia cells from patients with chronic lymphocytic leukemia (CLL), but not on normal B-cells or other postpartum tissues, ROR1 is an attractive candidate for targeted therapies. UC-961 is a first-in-class humanized monoclonal antibody that binds the extracellular domain of ROR1. In this article we outline some of the preclinical studies leading to an investigational new drug designation, enabling clinical studies in patients with CLL.

Original languageEnglish
Article number549
Pages (from-to)S167-S169
JournalClinical Lymphoma, Myeloma and Leukemia
Issue numberS
StatePublished - 1 Jun 2015
Externally publishedYes

Bibliographical note

Funding Information:
Conflicts of interest: none. Financial support for the conduct of the research was provided by the Leukemia Lymphoma Society (SCOR 7005-14), the National Institutes of Health grant for the CLL Research Consortium (P01-CA081534), and the California Institute of Regenerative Medicine (DR3-06924)

Publisher Copyright:
© 2015 The Authors.


  • AKT
  • CLL
  • Cirmtuzumab
  • Wnt receptor
  • cancer stem cell


Dive into the research topics of 'Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1'. Together they form a unique fingerprint.

Cite this